HEARTio
Category: AI in Healthcare
HEARTio is an AI-enabled cardiac diagnostics company using deep learning to analyze standard 12-lead ECGs to non-invasively detect coronary artery disease. HEARTio was founded in 2018. The company is led by Utkars Jain. Based in Pittsburgh, Pennsylvania, United States. Team size: 2-10. Total funding raised: $5.49M. Latest round: Seed. Key investors include Intelligence Ventures, Audacious Capital, VU Venture Partners, LifeX (Pittsburgh), Bessel, Shepherd Ventures III, Transform Health Ventures, Innovation Works, Allegheny Health Network, Richard King Mellon Foundation, HeartX Accelerator.
- Founded
- 2018
- Headquarters
- Pittsburgh, Pennsylvania, United States
- Team size
- 2-10
- Total funding
- $5.49M
Value proposition
AI-powered diagnostic platform that detects coronary artery disease from a routine ECG — faster, more accurately, and at lower cost than current standard of care, without contrast or radiation
Products and solutions
ECGio — AI platform that analyzes a standard 12-lead electrocardiogram (ECG) to non-invasively predict the presence, severity, and location of coronary artery disease (CAD)
Unique value
ECGio uses deep learning to detect microscopic, complex signal patterns invisible to the human eye on a standard 12-lead ECG, enabling non-invasive, rapid, and scalable prediction of coronary artery disease — democratizing cardiovascular care
Target customer
Emergency departments, hospitals, clinics, and healthcare professionals (cardiologists, emergency physicians)
Industries served
Healthcare, Cardiology, Emergency Medicine, Diagnostics
Technology advantage
Proprietary deep learning algorithms trained on large clinical datasets to detect coronary artery disease from standard 12-lead ECGs; FDA Breakthrough Device designation; peer-reviewed validation in JACC Advances (16,000+ patient cross-validation study) and Canadian Journal of Cardiology; cloud-based AI platform
How they differentiate
Unlike traditional cardiac diagnostics that require expensive imaging (CT angiography, stress tests, catheterization), HEARTio's ECGio uses only a standard ECG — the most common, low-cost cardiac test — combined with proprietary deep learning algorithms to predict CAD. The technology is backed by peer-reviewed validation studies on 16,000+ patients published in JACC Advances and the Canadian Journal of Cardiology. FDA Breakthrough Device designation.
Main competitors
CorVista Health, HeartFlow, Cleerly
Key partnerships
Innovation Works, Allegheny Health Network (AHN), Oracle Cloud Infrastructure (cloud partner), University of Pittsburgh (research origins)
Major milestones
2018: Company incorporated, 2020: Pre-seed funding raised (~$2M), 2022: Forbes 30 Under 30 recognition, FDA Breakthrough Device Designation for ECGio, 2024: Validation study published in Canadian Journal of Cardiology, 2025/2026: $4.25M seed round closed, 16,000+ patient cross-validation study published in JACC Advances, Partnerships with Innovation Works and Allegheny Health Network
Market positioning
Early-stage AI diagnostics company focused on non-invasive CAD detection from standard ECGs, competing against AI-based cardiac imaging platforms and traditional diagnostic pathways
Geographic focus
United States (primary), with expansion plans into European markets
Patents and IP
FDA Breakthrough Device Designation for ECGio; multiple peer-reviewed publications including JACC Advances and Canadian Journal of Cardiology
About Utkars Jain
PhD in Bioengineering at University of Pittsburgh; Applied Mathematics and Neuroscience (BS); Currently pursuing Wharton Executive MBA (WG'27); Forbes 30 Under 30 2024
Latest news about HEARTio
More AI in Healthcare companies
Official website: https://heartio.ai